Abiomed (ABMD) Tops Q2 EPS by 1c

Abiomed (NASDAQ: ABMD) reported Q2 EPS of $0.03, $0.01 better than the analyst estimate of $0.02. Revenue for the quarter came in at $51.8 million versus the consensus estimate of $48.8 million.

Abiomed sees FY2014 revenue of $209-212 million, versus prior guidance of $205-212 million and the consensus of $207.8 million.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Evogene (EVGN) Tops Q2 EPS by 15c